,author,keywords,pmc,pmid,prob,pubdate,title
0,L Yang; T Guo; DY Xia; LS Zhao,,,21777404,0.9994627833366394,2012,Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China.
1,CH Moon; HJ Lee; YS Jung; SH Lee; EJ Baik,,,9821211,0.9994612336158752,1998,"Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus."
2,KM Williamson; JH Patterson; RH McQueen; KF Adams; JA Pieper,,,9542475,0.9992725253105164,1998,Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers.
3,DJ Kazierad; DE Martin; RA Blum; DM Tenero; B Ilson; SC Boike; R Etheredge; DK Jorkasky,,,9357393,0.9990405440330505,1997,Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
4,JY Jia; MQ Zhang; YM Liu; Y Liu; GY Liu; SJ Li; C Lu; LP Weng; YL Qi; C Yu,,,20678685,0.9990339279174805,2010,"Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers."
5,G Wang; CQ Xiao; Z Li; D Guo; Y Chen; L Fan; RH Qian; XJ Peng; DL Hu; HH Zhou,,,19458107,0.9989890456199646,2009,Effect of soy extract administration on losartan pharmacokinetics in healthy female volunteers.
6,A Bienert; R Brzezińiski; E Szałek; V Dubai; E Grześkowiak; S Dyderski; L Drobnik; A Wolc; M Olejniczak-Rabinek,,,17220048,0.9989871382713318,2006,Bioequivalence study of two losartan formulations administered orally in healthy male volunteers.
7,DA Sica; MW Lo; WC Shaw; WF Keane; TW Gehr; CE Halstenson; K Lipschutz; CI Furtek; MA Ritter; S Shahinfar,,,18800456,0.9989418387413025,1995,The pharmacokinetics of losartan in renal insufficiency.
8,SH Yang; JS Choi; DH Choi,,,21709429,0.9989319443702698,2011,Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
9,DY Yoon; SI Park; JA Jung; YI Kim; IJ Jang; JY Chung,bioequivalence; dyslipidemia; fixed-dose combination; hypertension; loose combination; pharmacokinetics,,32109991,0.9987691044807434,2020,Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers.
10,SH Yang; YA Cho; JS Choi,,,21666702,0.9987083673477173,2011,Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats.
11,MW Lo; J Toh; SE Emmert; MA Ritter; CI Furtek; H Lu; WS Colucci; BF Uretsky; E Rucinska,,,9650542,0.9986990690231323,1998,Pharmacokinetics of intravenous and oral losartan in patients with heart failure.
12,MW Lo; MR Goldberg; JB McCrea; H Lu; CI Furtek; TD Bjornsson,,,8529329,0.9986258745193481,1995,"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans."
13,M Nakashima; K Umemura,,,8913542,0.9984787106513977,1996,The clinical pharmacology of losartan in Japanese subjects and patients.
14,AA Pedro; TW Gehr; DF Brophy; DA Sica,,,10761166,0.9984757304191589,2000,The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis.
15,AM Meadowcroft; KM Williamson; JH Patterson; AL Hinderliter; JA Pieper,,,10197301,0.9984409213066101,1999,"The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers."
16,IH Baek; BY Lee; ES Lee; KI Kwon,,,23539423,0.998331606388092,2013,Pharmacokinetics of angiotensin II receptor blockers in the dog following a single oral administration.
17,D Werner; U Werner; A Meybaum; B Schmidt; S Umbreen; A Grosch; HG Lestin; B Graf; O Zolk; MF Fromm,,,18399713,0.9982359409332275,2008,"Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers."
18,C Lv; C Wei; X Wang; H Yao; R Li; B Wang; R Guo,,,24132705,0.998065173625946,2014,The influence of food on the pharmacokinetics of amlodipine and losartan after single-dose of its compound tablets in healthy chinese subjects.
19,JF Marier; R Guilbaud; SR Kambhampati; P Mathew; J Moberly; J Lee; DE Salazar,,,16490807,0.997974693775177,2006,The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects.
20,CH Oliveira; R Medeiros Silva; V Santagada; G Caliendo; E Perissutti; M Prado Galuppo; V Marcondes Rezende; RE Barrientos-Astigarraga; GD Mendes; G De Nucci,,,16550737,0.9978043437004089,2006,Comparative bioavailability of two losartan formulations in healthy human volunteers after a single dose administration.
21,I Jeon; SJ Moon; SI Park; Y Choi; J Jung; KS Yu; JY Chung,amlodipine; chlorthalidone; fixed-dose combination; hypertension; losartan,,34159751,0.9977032542228699,2021,Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan and Chlorthalidone Compared to Concurrent Administration of the Separate Components.
22,Z Li; G Wang; LS Wang; W Zhang; ZR Tan; L Fan; BL Chen; Q Li; J Liu; JH Tu; DL Hu; ZQ Liu; HH Zhou,,,19604036,0.997384250164032,2009,Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.
23,M Ohtawa; F Takayama; K Saitoh; T Yoshinaga; M Nakashima,,,8471405,0.9971919655799866,1993,"Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans."
24,YD Yan; HK Kim; KH Seo; WS Lee; GS Lee; JS Woo; CS Yong; HG Choi,,,20849146,0.9968761205673218,2010,"The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174."
25,M Spanakis; IS Vizirianakis; G Batzias; I Niopas,,,23327826,0.996450662612915,2013,Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits.
26,F Demirkaya-Miloglu; ME Yaman; Y Kadioglu,Losartan potassium; pharmacokinetic; rabbit plasma; spectrofluorimetry,,24890844,0.9964154958724976,2015,A new spectrofluorimetric method for determination of losartan potassium in rabbit plasma and its application to pharmacokinetic study.
27,PC Wong; DD Christ; YN Wong; GN Lam,,,8966199,0.9963371753692627,1996,"Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan."
28,S Kumar; T Monif; A Khuroo; S Reyar; R Jain; AK Singla; K Kurachi,,,24290414,0.9961645603179932,2014,Pharmacokinetic comparison and bioequivalence evaluation of losartan/ hydrochlorothiazide tablet between Asian Indian and Japanese volunteers.
29,CR Lee; JA Pieper; AL Hinderliter; JA Blaisdell; JA Goldstein,,,12820813,0.9960055947303772,2003,"Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals."
30,SM Lankford; D Plummer; P Hellyer; DD Christ; SA Bai,,,9388040,0.9956777691841125,1997,Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model.
31,JJ Tamimi; II Salem; S Mahmood Alam; Q Zaman; R Dham,,,15906418,0.9956578016281128,2005,Comparative pharmacokinetics of two tablet formulations of Losartan: bioequivalence assessment.
32,DH Choi; C Li; JS Choi,,,20636879,0.9954480528831482,2010,"Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin."
33,Q Zhao; J Wei; H Zhang,CYP3A4; Losartan; P-gp; herb–drug interaction; quercetin,,29768080,0.9953411817550659,2019,Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats.
34,T Yoshitani; H Yagi; N Inotsume; M Yasuhara,,,12186413,0.9953239560127258,2002,Effect of experimental renal failure on the pharmacokinetics of losartan in rats.
35,M Kobayashi; M Takagi; K Fukumoto; R Kato; K Tanaka; K Ueno,,,18445991,0.9951422214508057,2008,"The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan."
36,Q Pei; JY Liu; JY Yin; GP Yang; SK Liu; Y Zheng; P Xie; CX Guo; M Luo; HH Zhou; X Li; ZQ Liu,Drug interactions; Irbesartan; Pharmacodynamics; Pharmacokinetics; Polymorphism; Repaglinide; SLCO1B1,,29748863,0.9948936700820923,2018,Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
37,JW Bae; CI Choi; HI Lee; YJ Lee; CG Jang; SY Lee,,,22735459,0.9946139454841614,2012,Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
38,J Zhi; R Moore; L Kanitra; TE Mulligan,,,12211217,0.9941383600234985,2002,Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects.
39,T Cabaleiro; M Román; D Ochoa; M Talegón; R Prieto-Pérez; A Wojnicz; R López-Rodríguez; J Novalbos; F Abad-Santos,,,23118328,0.9941072463989258,2013,"Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers."
40,M De Smet; DF Schoors; G De Meyer; R Verbesselt; MR Goldberg; V Fitzpatrick; G Somers,,,8703664,0.9939888715744019,1995,Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers.
41,Y Choi; S Lee; SM Cho; WH Kang; KY Nam; IJ Jang; KS Yu,amlodipine; comparative pharmacokinetics; drug development; losartan,,27703330,0.9934327602386475,2016,"Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study."
42,SH Ryu; YS Kim; HJ Jang; KB Kim,,,26514876,0.9934229254722595,2015,"Negligible Pharmacokinetic Interaction of Red Ginseng and Losartan, an Antihypertensive Agent, in Sprague-Dawley Rats."
43,HW Lee; HY Ji; ES Park; KC Lee; HS Lee,,,19536783,0.9932094216346741,2009,Hydrophilic interaction chromatography-tandem mass spectrometric analysis of irbesartan in human plasma: application to pharmacokinetic study of irbesartan.
44,Y Han; D Guo; Y Chen; Y Chen; ZR Tan; HH Zhou,,,19221727,0.993104875087738,2009,Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.
45,K Sekino; T Kubota; Y Okada; Y Yamada; K Yamamoto; R Horiuchi; K Kimura; T Iga,,,14504849,0.9930906295776367,2003,Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.
46,HX Huang; H Wu; Y Zhao; T Zhou; X Ai; Y Dong; Y Zhang; Y Lai,Breviscapine; CYP2C9; E-3174; losartan; pharmacokinetics; polymorphism,,33509019,0.9925093650817871,2021,Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects.
47,A Ahad; M Raish; YA Bin Jardan; MA Alam; AM Al-Mohizea; FI Al-Jenoobi,Ginger; Hibiscus sabdariffa; losartan; pharmacodynamic; pharmacokinetic,,32048541,0.9920279383659363,2020,Effect of Hibiscus sabdariffa and Zingiber officinale on the antihypertensive activity and pharmacokinetic of losartan in hypertensive rats.
48,SK Bae; MJ Kim; EJ Shim; DY Cho; JH Shon; KH Liu; EY Kim; JG Shin,,,19277953,0.9920116066932678,2009,HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies.
49,B Lin; G Lin; X Liu; J Ma; X Wang; F Lin; L Hu,Artificial neural network; back-propagation; losartan; pharmacokinetics,,26885213,0.991874635219574,2015,Application of back-propagation artificial neural network and curve estimation in pharmacokinetics of losartan in rabbit.
50,B Dong; S Yuan; J Hu; Y Yan,CYP3A4; Herb–drug interaction; metabolism,,29953302,0.9918534159660339,2018,Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism.
51,W Ma; L Lv; J Guo; Y Meng; Y Wang; X Yang; L Zhu; H Nian; L Zhao,,,31511782,0.9917912483215332,2019,Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study.
52,U Yasar; C Forslund-Bergengren; G Tybring; P Dorado; A Llerena; F Sjöqvist; E Eliasson; ML Dahl,,,11823761,0.9911534190177917,2002,Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
53,DD Christ; PC Wong; YN Wong; SD Hart; CY Quon; GN Lam,,,8138932,0.991119921207428,1994,The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog.
54,R Zaidenstein; S Soback; M Gips; B Avni; V Dishi; Y Weissgarten; A Golik; E Scapa,,,11477318,0.9910871386528015,2001,Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.
55,U Yasar; E Eliasson; C Forslund-Bergengren; G Tybring; M Gadd; F Sjöqvist; ML Dahl,,,11829203,0.9910332560539246,2001,The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.
56,H Li; L Liu; L Xie; D Gan; X Jiang,CYP450; LC–MS; drug–drug interaction,,27327872,0.9906011819839478,2016,Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism.
57,R Dubey; M Ghosh; BN Sinha; V Muthukrishnan,,,25947361,0.9904606938362122,2015,"Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS."
58,Y Wu; Z Mao; Y Liu; X Wang; X Di,Febuxostat; Human plasma; LC–MS/MS; Metabolites; Pharmacokinetics,,26072013,0.9891970753669739,2015,Simultaneous determination of febuxostat and its three active metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in Chinese healthy volunteers.
59,MS Shams; MI Alam; A Ali; Y Sultana; M Aqil; F Shakeel,,,21038845,0.9889891743659973,2010,Pharmacokinetics of a losartan potassium released from a transdermal therapeutic system for the treatment of hypertension.
60,BD Snyder; A Rowland; TM Polasek; JO Miners; MP Doogue,,,25028073,0.9889784455299377,2014,Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
61,SJ Moon; SY Kim; CH Lim; HB Jang; MG Kim; JY Jeon,DW1029M; botanical drug; diabetic nephropathy; drug interaction; pharmacokinetic,,27739231,0.9876847267150879,2017,"Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers."
62,JS Choi; JS Choi; DH Choi,,,24380237,0.9862500429153442,2013,"Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats."
63,TZ Dickson; J Zagrobelny; CC Lin; MA Ritter; D Snavely; D Ramjit; S Shahinfar; MW Lo,,,12817522,0.9862237572669983,2003,"Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment."
64,KM Kaukonen; KT Olkkola; PJ Neuvonen,,,9551703,0.9854069948196411,1998,Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
65,JY Lee; JH Park; KT Kim; J Yu; PK Sahu; N Kang; HJ Shin; MH Kim; JS Kim; IS Yoon; LS Jeong; DD Kim,Adenosine analogues; LC–MS/MS; LJ-2698; Pharmacokinetics; Validation; hA3 AR antagonist,,28756559,0.9853354692459106,2017,"Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study."
66,R Dubey; M Ghosh,LC-MS/MS; Pharmacokinetic; Plasma; Simultaneous estimation; Validation,,26839805,0.9850185513496399,2015,"Simultaneous Determination and Pharmacokinetic Study of Losartan, Losartan Carboxylic Acid, Ramipril, Ramiprilat, and Hydrochlorothiazide in Rat Plasma by a Liquid Chromatography/Tandem Mass Spectrometry Method."
67,R Wang; H Zhang; Y Wang; X Yu; Y Yuan,Cytochrome P450; Drug metabolism; Losartan; Salvia miltiorrhiza Bunge; Salvianolic acid B; Tanshinone IIA,,26806573,0.9844175577163696,2016,Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9.
68,M Någård; WG Kramer; DW Boulton,drug interactions; gastric pH-sensitive drugs; hyperkalemia; pharmacokinetic analysis; sodium zirconium cyclosilicate,,34221388,0.9841618537902832,2021,"Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults."
69,YN Wong; KA Holm; DL Burcham; SM Huang; CY Quon,,,8161716,0.9837701320648193,1994,"The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs."
70,JB McCrea; MW Lo; L Tomasko; CC Lin; JY Hsieh; NL Capra; MR Goldberg,,,8750372,0.9830312728881836,1995,Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide.
71,D Williams; X Tao; L Zhu; M Stonier; JD Lutz; E Masson; S Zhang; B Ganguly; Z Tzogas; S Lubin; B Murthy,Biologics; cytochrome P450; interaction; pharmacokinetics; transplantation,,27552251,0.9826179146766663,2017,"Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator."
72,JW Park; KA Kim; Y Il Kim; JY Park,amlodipine; interactions; losartan; pharmacodynamics; pharmacokinetics,,31058419,0.9824165105819702,2019,Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings.
73,K Li; L Ding; ZL Yang; EH Liu; LW Qi; P Li; YZ Hu,,,19795392,0.9778941869735718,2010,Determination of asperosaponin VI in rat plasma by HPLC-ESI-MS and its application to preliminary pharmacokinetic studies.
74,Y Guo; Y Chen; ZR Tan; CD Klaassen; HH Zhou,,,21870106,0.9736863970756531,2012,Repeated administration of berberine inhibits cytochromes P450 in humans.
75,E Karatza; V Karalis,delay differential equations; gastric emptying; losartan; parent-metabolite model; population pharmacokinetics,,31514255,0.9726251363754272,2020,Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174.
76,MR Goldberg; MW Lo; TE Bradstreet; MA Ritter; P Höglund,,,8751032,0.9711425304412842,1995,"Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist."
77,PC Wong; SM Huang; RJ Ardecky; DJ Carini; AT Chiu; WA Price; AM Agra; RR Wexler; PB Timmermans,,,8563699,0.970610499382019,1995,Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811.
78,B Fuchs; K Breithaupt-Grögler; GG Belz; S Roll; C Malerczyk; V Herrmann; H Spahn-Langguth; E Mutschler,,,11045887,0.9678777456283569,2000,Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man.
79,R Thakur; MK Anwer; MS Shams; A Ali; RK Khar; F Shakeel; EI Taha,,,19527115,0.9676746726036072,2009,Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation.
80,HB Shin; EH Jung; P Kang; CW Lim; KY Oh; CK Cho; YJ Lee; CI Choi; CG Jang; SY Lee; JW Bae,ABCB1; Diplotype; Losartan; MDR1; Pharmacogenomics; Pharmacokinetics,,33249530,0.9670761227607727,2020,ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan.
81,SZ Chen; PP Pan; SH Wang; J Luo; GX Hu; SS Xu; L Zhang; YF Yu,,,25823852,0.9630657434463501,2015,In vitro and in vivo drug-drug interaction of losartan and glimepiride in rats and its possible mechanism.
82,TL Fischer; JA Pieper; DW Graff; JE Rodgers; JD Fischer; KJ Parnell; JA Goldstein; R Greenwood; JH Patterson,,,12235444,0.9612886905670166,2002,Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers.
83,S Uchida; S Tanaka; N Namiki,cocktail approach; cytochrome P450; drug interaction; pharmacokinetics; rat,,24395703,0.9590045213699341,2014,Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
84,AK Das; S Dhanure; AK Savalia; SK Nayak; SK Tripathy,ANOVA; Losartan Potassium; angiotensin; bioequivalence; hypertension,,26009652,0.958100438117981,2015,Human bioequivalence evaluation of two losartan potassium tablets under fasting conditions.
85,CR Lee; JA Pieper; RF Frye; AL Hinderliter; JA Blaisdell; JA Goldstein,,,12520632,0.9579265713691711,2003,"Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans."
86,E Chong; V Kalia; S Willsie; P Winkle,Chronic kidney disease; Hyperphosphatemia; Pharmacokinetics; Phase I; Sucroferric oxyhydroxide,,24699894,0.9529289603233337,2014,"Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects."
87,M Sasaki; A Fujimura; K Harada; K Sunaga; A Ebihara,,,8739018,0.9497973322868347,1996,"Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension."
88,M Kusama; K Maeda; K Chiba; A Aoyama; Y Sugiyama,,,19082874,0.9493480920791626,2009,Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.
89,RP McNeill; M Zhang; MJ Epton; MP Doogue,chronic obstructive pulmonary disease; cytochrome P450; drug metabolism; pharmacokinetics; therapeutics,,33855722,0.9481663703918457,2021,Drug metabolism in severe chronic obstructive pulmonary disease: A phenotyping cocktail study.
90,OG Gribakina; GB Kolyvanov; AA Litvin; VP Zherdev; SB Seredin,,,23767102,0.9451608657836914,2013,[In vivo study of the pharmacokinetic interaction of afobazole and losartan (cytochrome CYP2C9 substrate)].
91,N Idkaidek; T Arafat,,,22784220,0.9449619650840759,2012,Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system.
92,MC Salvadori; RF Moreira; BC Borges; MH Andraus; CP Azevedo; RA Moreno; NC Borges,,,19811351,0.9444015622138977,2009,Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics.
93,DAC Cusinato; EZ Martinez; MTC Cintra; GCO Filgueira; AA Berretta; VL Lanchote; EB Coelho,Clinical trials; Drug metabolism; Drug transport; Pharmacokinetics; Propolis,,31442620,0.9415059685707092,2019,Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach.
94,P Gardiner; SW Paine,,,21778353,0.9412009716033936,2011,The impact of hepatic uptake on the pharmacokinetics of organic anions.
95,E Puris; M Pasanen; VP Ranta; M Gynther; A Petsalo; P Käkelä; V Männistö; J Pihlajamäki,absorption; cocktail; cytochrome P450; obesity; pharmacokinetics,,30916845,0.9404770135879517,2019,"Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates."
96,MR Goldberg; MW Lo; PJ Deutsch; SE Wilson; EJ McWilliams; JB McCrea,,,8653989,0.9331978559494019,1996,Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174.
97,TW Kim; BW Yoo; JK Lee; JH Kim; KT Lee; YH Chi; JY Lee,,,22264484,0.9309312105178833,2012,Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.
98,SG Gadepalli; P Deme; M Kuncha; R Sistla,Amlodipine; Exforge HCT; Hydrochlorothiazide; Polypill; Valsartan,,29403906,0.928628146648407,2014,"Simultaneous determination of amlodipine, valsartan and hydrochlorothiazide by LC-ESI-MS/MS and its application to pharmacokinetics in rats."
99,AN Kong; L Tomasko; SA Waldman; B Osborne; PJ Deutsch; MR Goldberg; TD Bjornsson,,,8568008,0.9265280365943909,1995,Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin.
100,E Karatza; V Karalis,,,33768449,0.9241439700126648,2021,Investigating the Impact of Gastric Emptying on Pharmacokinetic Parameters Using Delay Differential Equations and Principal Component Analysis.
101,N Daneshtalab; RZ Lewanczuk; AS Russell; F Jamali,,,17050800,0.9220418930053711,2006,Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis.
102,A Ahad; M Raish; YA Bin Jardan; MA Alam; AM Al-Mohizea; FI Al-Jenoobi,L-NAME; Losartan; Nigella Sativa; Pharmacodynamic; Pharmacokinetic; Trigonella Foenum-graecum,,32994710,0.9216344356536865,2020,Potential pharmacodynamic and pharmacokinetic interactions of Nigella Sativa and Trigonella Foenum-graecum with losartan in L-NAME induced hypertensive rats.
103,NI Abou Obaid; FI Al-Jenoobi; MA Ibrahim; MA Alam,Losartan potassium; extrusion/spheronization; matrix pellet; pharmacokinetics; sustained release,,32538215,0.9192519783973694,2020,Losartan potassium sustained release pellets with improved in vitro and in vivo performance.
104,JK Heo; HJ Kim; GH Lee; B Ohk; S Lee; KS Song; IS Song; KH Liu; YR Yoon,cytochrome P450; drug interaction; liquid chromatography-tandem mass spectrometry; organic anion transporting polypeptide; pharmacokinetics,,30004443,0.913209080696106,2018,Simultaneous Determination of Five Cytochrome P450 Probe Substrates and Their Metabolites and Organic Anion Transporting Polypeptide Probe Substrate in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry.
105,DA Sica; CE Halstenson; TW Gehr; WF Keane,,,10885588,0.9104247093200684,2000,Pharmacokinetics and blood pressure response of losartan in end-stage renal disease.
106,H Li; MJ Canet; JD Clarke; D Billheimer; SA Xanthakos; JE Lavine; RP Erickson; NJ Cherrington,,,28986475,0.907610297203064,2017,Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.
107,OG Gribakina; GB Kolyvanov; AA Litvin; VV Smirnov; RV Shevchenko; VP Zherdev,,,27051923,0.906458854675293,2015,[EVALUATION OF THE PHARMACOKINETIC INTERACTION OF AFOBAZOLE WITH CYP2C9 ENZYME DRUG SUBSTRATE OF CYTOCHROME P450].
108,M Azizi; G Chatellier; L Nicolet; T Guyene; J Hempenius; J Ménard,,,28425793,0.9034534096717834,2000,Is it Possible to Differentiate between Angiotensin II Type 1 (AT1) Receptor Blockers in Normotensive Volunteers?
109,M Azizi; G Chatellier; TT Guyene; D Murieta-Geoffroy; J Ménard,,,7641363,0.9027085900306702,1995,Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
110,AC Liu; LX Zhao; J Xing; T Liu; FY Du; HX Lou,,,22293343,0.9023860692977905,2012,Pre-treatment with curcumin enhances plasma concentrations of losartan and its metabolite EXP3174 in rats.
111,NW Kang; JY Lee; K Song; MH Kim; S Yoon; DT Nguyen; S Kim; YS Kim; DD Kim,"7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone; Keywords: ECN; LC-MS/MS; Pharmacokinetics; Tussilago farfara Linnaeus; Validation",,32294941,0.8969160914421082,2020,"Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats."
112,B Noël; G Del Re; P Capone; HR Brunner; J Nussberger,,,8856481,0.8966888785362244,1996,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081.
113,R Neves; S Almeida; A Filipe; AC Spínola; Z Abolfathi; M Yritia; J Ortuño,,,18807576,0.8961611390113831,2008,Bioequivalence study of two different film-coated tablet formulations of losartan-hydrochlorothiazide in healthy volunteers.
114,F de Andrés; S Terán; M Bovera; H Fariñas; E Terán; A LLerena,,,26600202,0.8920543789863586,2016,"Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach."
115,DS Kim; Y Kim; JY Jeon; MG Kim,P-glycoprotein; Red Ginseng; cytochrome P450; drug interaction,,27746690,0.8906806707382202,2016,Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers.
116,A Munafo; Y Christen; J Nussberger; LY Shum; RM Borland; RJ Lee; B Waeber; J Biollaz; HR Brunner,,,1587065,0.8903648257255554,1992,"Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist."
117,JW Bae; CI Choi; MJ Kim; DH Oh; SK Keum; JI Park; BH Kim; HK Bang; SG Oh; BS Kang; HJ Park; HD Kim; JH Ha; HJ Shin; YH Kim; HS Na; MW Chung; CG Jang; SY Lee,,,21841812,0.8869853615760803,2011,Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
118,SKS Adiraju; K Shekar; P Tesar; R Naidoo; I Rapchuk; S Belz; JF Fraser; MT Smith; S Ghassabian,"cardiopulmonary bypass; cytochrome P450 (CYP), CYP phenotyping; extracorporeal circulation; extracorporeal membrane oxygenation",,31164617,0.8854450583457947,2019,"Study Protocol for a Pilot, Open-Label, Prospective, and Observational Study to Evaluate the Pharmacokinetics of Drugs Administered to Patients during Extracorporeal Circulation; Potential of In Vivo Cytochrome P450 Phenotyping to Optimise Pharmacotherapy."
119,M Miura; S Tanaka; S Uchida; C Kamiya; N Katayama; A Hakamata; K Odagiri; N Inui; J Kawakami; H Watanabe; N Namiki,CYP; cocktail study; limited-point sampling,,34078808,0.8758422136306763,2021,Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities.
120,Y Yuan; H Zhang; W Ma; S Sun; B Wang; L Zhao; G Zhang; Y Chai,Exp3174 (losartan carboxylic acid); herb-drug interactions; liquid chromatography tandem mass spectrometry; losartan; pharmacokinetics,,23722257,0.86586594581604,2013,Influence of compound danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry.
121,PK Yeung; A Jamieson; GJ Smith; D Fice; PT Pollak,,,11011981,0.8497780561447144,2000,Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection.
122,GA Salah; HM Abd El-Wadood; M Khairy; AA Khorshed,"2,3,5,6 tetrachloro-1,4-benzoquinone; candesartan valsartan; irbesartan; losartan; olmesartan",,27943353,0.8476047515869141,2017,Two selective HPTLC methods for determination of some angiotensin II receptor antagonists in tablets and biological fluids.
123,J Zhou; M Chen; Y Li; F Yu; X Cheng; Y Yang; Y Liu; X Xie; Z Li; H Zhang; X Mei,On-line solid phase extraction; dog plasma; liquid chromatography-tandem mass spectrometry; metolazone; valsartan,,29028382,0.8437994718551636,2017,Simultaneous determination of metolazone and valsartan in plasma by on-line SPE coupled with liquid chromatography/tandem mass spectrometry.
124,VK Karra; NR Pilli; JK Inamadugu; JV Rao,Amlodipine; liquid chromatography-tandem mass spectrometric method; losartan; losartan acid; pharmacokinetics,,23781473,0.843632698059082,2012,"Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study."
125,DAC Cusinato; GCO Filgueira; A Rocha; MACT Cintra; VL Lanchote; EB Coelho,Liquid Chromatography; Mass Spectrometry,,30445356,0.8431043028831482,2019,LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses.
126,K Yamada; SN Iyer; MC Chappell; D Ganten; CM Ferrario,,,9740616,0.8408194780349731,1998,Converting enzyme determines plasma clearance of angiotensin-(1-7).
127,HJ Shah; ML Kundlik; NK Patel; G Subbaiah; DM Patel; BN Suhagia; CN Patel,,,19750501,0.8357083201408386,2009,Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS.
128,MA Vernace; PF Mento; ME Maita; BM Wilkes,,,8206617,0.8326919078826904,1994,Effects of angiotensin receptor subtype inhibitors on plasma angiotensin clearance.
129,SS Khandave; SV Sawant; RV Sahane; V Murthi; SS Dhanure; PG Surve,,,22541840,0.8246579766273499,2012,Bioequivalence study of two losartan tablet formulations with special emphasis on cardiac safety.
130,JL Reid,,,8903052,0.8241761922836304,1995,"Pharmacodynamic, pharmacokinetic and clinical profile of the first orally active angiotensin II receptor antagonist."
131,MC Boruban; U Yasar; MO Babaoglu; O Sencan; A Bozkurt,,,17024799,0.8241727352142334,2006,Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients.
132,A Wennerholm; A Nordmark; M Pihlsgård; M Mahindi; L Bertilsson; LL Gustafsson,,,16783563,0.8226813673973083,2006,"Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo."
133,M Nematbakhsh; F Ashrafi; T Safari; A Talebi; H Nasri; M Mortazavi; M Khazaei; MM Baradaran-Mahdavi,,,21928232,0.8215115666389465,2012,Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats.
134,S Tsuruoka; M Wakaumi; N Araki; T Ioka; K Sugimoto; A Fujimura,,,16239366,0.8157501816749573,2005,Comparative study of taste disturbance by losartan and perindopril in healthy volunteers.
135,F Kolocouri; Y Dotsikas; C Apostolou; C Kousoulos; YL Loukas,,,17119933,0.8126137256622314,2007,"Simultaneous determination of losartan, EXP-3174 and hydrochlorothiazide in plasma via fully automated 96-well-format-based solid-phase extraction and liquid chromatography-negative electrospray tandem mass spectrometry."
136,CD Scripture; JA Pieper,,,11368292,0.8061038851737976,2001,Clinical pharmacokinetics of fluvastatin.
137,AK Shakya; YM Al-Hiari; OM Alhamami,,,17118719,0.8026784658432007,2007,Liquid chromatographic determination of irbesartan in human plasma.
138,KS Oh; SJ Park; DD Shinde; JG Shin; DH Kim,,,22483397,0.7830896973609924,2012,High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma.
139,N Treijtel; C Collins; M van Bruijnsvoort; R Fuhr; E Ernault; S Gangaram-Panday; P Passier,ASP8477; cytochrome P450; drug-drug interaction; inhibition; nonlinear pharmacokinetics,,30730615,0.7711157202720642,2019,A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
140,T Bosch; T Wendler,,,15274676,0.7540040612220764,2004,Efficacy and safety of DALI-LDL-apheresis in two patients treated with the angiotensin II-receptor 1 antagonist losartan.
141,H Amini; A Ahmadiani; M Moazenzadeh,,,17523724,0.7473339438438416,2004,Pharmacokinetics of Losartan and its Active Metabolite EXP3174 in Healthy Iranian Subjects.
142,J Lill; LA Bauer; JR Horn; PD Hansten,,,10984808,0.7471122741699219,2000,Cyclosporine-drug interactions and the influence of patient age.
143,YF Zheng; SH Bae; Z Huang; SU Chae; SJ Jo; HJ Shim; CB Lee; D Kim; H Yoo; SK Bae,(‒)-sophoranone; CYP2C9; drug interaction; high plasma protein binding; in vitro; in vivo; low permeability; potent inhibition,,32272615,0.7452725768089294,2020,Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone.
144,HT Tran; JB Park; KH Hong; HG Choi; HK Han; J Lee; KT Oh; BJ Lee,,,21641985,0.7409552931785583,2011,Preparation and characterization of pH-independent sustained release tablet containing solid dispersion granules of a poorly water-soluble drug.
145,C He; Y Liu; Y Wang; J Tang; Z Tan; X Li; Y Chen; Y Huang; X Chen; D Ouyang; H Zhou; J Peng,EXP3174; LC-MS/MS; Losartan; NMR; Pharmacokinetics; Pharmacometabolomics,,30041085,0.7379677891731262,2018,1H NMR based pharmacometabolomics analysis of metabolic phenotype on predicting metabolism characteristics of losartan in healthy volunteers.
146,JC Song; CM White,,,10678291,0.7328291535377502,2000,"Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists."
147,A Zarghi; SM Foroutan; A Shafaati; A Khoddam,,,16294502,0.7323907613754272,2005,A rapid HPLC method for the determination of losartan in human plasma using a monolithic column.
148,SN Iyer; MC Chappell; KB Brosnihan; CM Ferrario,,,9514193,0.7322195768356323,1998,Role of AT1 and AT2 receptors in the plasma clearance of angiotensin II.
149,A Tronde; B Nordén; H Marchner; AK Wendel; H Lennernäs; UH Bengtsson,,,12761811,0.7315952777862549,2003,Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs.
150,M Donzelli; A Derungs; MG Serratore; C Noppen; L Nezic; S Krähenbühl; M Haschke,,,24218006,0.7299841642379761,2014,"The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots."
151,C Almansa; LA Gómez; FL Cavalcanti; AF de Arriba; J García-Rafanell; J Forn,,,9046346,0.72980797290802,1997,Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.
152,FS Falvella; S Marelli; S Cheli; S Montanelli; F Viecca; L Salvi; A Ferrara; E Clementi; G Trifirò; A Pini,,,27474842,0.7190973162651062,2016,Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?
153,P Sandwall; MW Lo; B Jonzon; P Dalén; C Furtek; M Ritter; G Alván; J McCrea; F Sjöqvist,,,10424320,0.7185840606689453,1999,Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
154,A Gunes; E Bilir; H Zengil; MO Babaoglu; A Bozkurt; U Yasar,,,17516991,0.714604914188385,2007,Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
155,A Derungs; M Donzelli; B Berger; C Noppen; S Krähenbühl; M Haschke,,,26123704,0.7072545289993286,2016,Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
156,Y Hu; X Zhou; H Shi; W Shi; S Ye; H Zhang,LC-MS; herb-drug interaction; losartan; pharmacokinetics; tripterygium glucoside tablet,,28299812,0.7055022716522217,2017,The effect of tripterygium glucoside tablet on pharmacokinetics of losartan and its metabolite EXP3174 in rats.
157,DA Sica; TW Gehr; S Ghosh,,,16029066,0.7040883302688599,2005,Clinical pharmacokinetics of losartan.
158,A Rowland; M van Dyk; D Warncken; AA Mangoni; MJ Sorich; A Rowland,cytochrome P450; drug interaction,,29178272,0.7007157206535339,2018,Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.
159,BS Huang; M Ahmad; J Tan; FH Leenen,,,19617416,0.6881664395332336,2009,Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction.
160,YL Wei; HJ Du; YP Lin; ML Wu; RA Xu,Cocktail; Cytochrome P450; Enzyme; Herb-drug interaction; Salidroside,,29796228,0.6867888569831848,2018,Effects of salidroside on rat CYP enzymes by a cocktail of probe drugs.
161,A Mascarello; H Azevedo; MA Ferreira Junior; EE Ishikawa; CRW Guimarães,Angiotensin; Antihypertensive; Codrug; Losartan; Neprilysin; Prodrug,,33493668,0.6834720969200134,2021,"Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition."
162,X Bao; W Zhu; R Zhang; C Wen; L Wang; Y Yan; H Tang; Z Chen,AT(1) receptor antagonist; Angiotensin II; Anti-hypertension; Hypertension,,27004954,0.680954098701477,2016,Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs.
163,HQ Nguyen; J Lin; E Kimoto; E Callegari; S Tse; RS Obach,hepatic metabolism; hepatobiliary disposition; mathematical model; physiologically based pharmacokinetic modeling; transporters,,28412400,0.6803393363952637,2017,Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.
164,MG Kim; Y Kim; JY Jeon; DS Kim,P-glycoprotein; cytochrome P450; drug interaction; fermented red ginseng,,27495955,0.6785135865211487,2016,"Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach."
165,XF Han; X He; M Wang; D Xu; LP Hao; AH Liang; J Zhang; ZM Zhou,Antihypertension; Benzimidazole; Chiral drug; Low-toxicity; Molecular docking,,26397395,0.6715896725654602,2015,"Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center."
166,M Azizi; G Chatellier; TT Guyene; J Ménard,,,10404959,0.6665580868721008,1999,Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
167,RJ MacFadyen; CR Jones; JK Doig; H Birnbock; JL Reid,,,7769797,0.6392627954483032,1995,"Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans."
168,G Bakris; E Burgess; M Weir; G Davidai; S Koval; ,,,18496508,0.6366524696350098,2008,Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
169,CI Furtek; MW Lo,,,1601963,0.6233549118041992,1992,"Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography."
170,C Lindamood; S Ortiz; A Shaw; R Rackley; JC Gorski,,,20489028,0.6231710910797119,2011,Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.
171,G Wuerzner; M Azizi,,,18307734,0.6056293845176697,2008,Renin inhibition with aliskiren.
172,D Farthing; D Sica; I Fakhry; A Pedro; TW Gehr,,,9518174,0.6002137064933777,1997,"Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate."
173,R Koytchev; Y Ozalp; A Erenmemisoglu; MJ van der Meer; RS Alpan,,,15497669,0.5993989706039429,2004,Combination of losartan and hydrochlorothiazide: in vivo bioequivalence.
174,J Sun; W Xu; H Hua; Y Xiao; X Chen; Z Gao; S Li; X Jing; F Du; G Sun,Angiotensin receptor blocker; Angiotensin receptor-NEP inhibitor; Heart failure; Neprilysin inhibitor,,32570118,0.592857837677002,2020,"Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor."
175,SG Spence; AG Zacchei; LL Lee; CL Baldwin; RA Berna; BA Mattson; RS Eydelloth,,,8864166,0.5904512405395508,1996,Toxicokinetic analysis of losartan during gestation and lactation in the rat.
176,X Li; J Sun; Z Guo; D Zhong; X Chen,,,31076412,0.587679922580719,2019,"Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans."
177,B Bunkenburg; C Schnell; HP Baum; F Cumin; JM Wood,,,1889842,0.5756194591522217,1991,Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences.
178,E Rojas-Campos; L Cortés-Sanabria; HR Martínez-Ramírez; L González; F Martín-del-Campo; M González-Ortiz; AM Cueto-Manzano,,,16411525,0.5720539689064026,2005,"Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients."
179,M Burnier; T Buclin; J Biollaz; J Nussberger; B Waeber; HR Brunner,,,8743506,0.5705307126045227,1996,Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
180,NA Charoo; R Cristofoletti; AR Khatri; AA Ali,ADME; bioavailability; bioequivalence; metabolite; parent drug; pharmacokinetics; pharmacodynamics; losartan potassium; metabolism; oral absorption,,24700383,0.5509116053581238,2014,Significance of metabolites in bioequivalence: losartan potassium as a case study.
181,HR Brunner,,,9438775,0.5497342944145203,1997,"The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations."
182,JM Mallion; JP Badguet,,,11086634,0.5411182045936584,2000,Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
183,J Nicolaï; T De Bruyn; L Thevelin; P Augustijns; P Annaert,,,26712820,0.5307996869087219,2016,Transport-Metabolism Interplay of Atazanavir in Rat Hepatocytes.
184,J Zhuo; D Thomas; PJ Harris; SL Skinner,,,1464825,0.5283002257347107,1992,The role of endogenous angiotensin II in the regulation of renal haemodynamics and proximal fluid reabsorption in the rat.
185,A Soldner; U Christians; M Susanto; VJ Wacher; JA Silverman; LZ Benet,,,10227700,0.5259903073310852,1999,Grapefruit juice activates P-glycoprotein-mediated drug transport.
186,MA Alam; NI Abou Obaid; MA Ibrahim; M Raish; FI Al-Jenoobi,,,30668856,0.5237201452255249,2019,A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma.
187,S Mitsuyama,,,17571369,0.5221261382102966,2007,"[ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects]."
188,A Tronde; B Nordén; AB Jeppsson; P Brunmark; E Nilsson; H Lennernäs; UH Bengtsson,,,12852442,0.5126880407333374,2003,Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability.
189,Y Zhang; L Miao; L Lin; CY Ren; JX Liu; YM Cui,CYP450; Crocus sativus; Ginkgo biloba; Herb-drug interaction; Panax ginseng; Sailuotong,,29425645,0.5120024085044861,2018,"Repeated administration of Sailuotong, a fixed combination of Panax ginseng, Ginkgo biloba, and Crocus sativus extracts for vascular dementia, alters CYP450 activities in rats."
190,K Hosoya; T Ishimitsu,,,12177688,0.5083160996437073,2002,"Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor."
